Craig B. Davis

7.1k total citations · 1 hit paper
38 papers, 4.5k citations indexed

About

Craig B. Davis is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Craig B. Davis has authored 38 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Immunology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Craig B. Davis's work include Immune Cell Function and Interaction (13 papers), T-cell and B-cell Immunology (11 papers) and CAR-T cell therapy research (9 papers). Craig B. Davis is often cited by papers focused on Immune Cell Function and Interaction (13 papers), T-cell and B-cell Immunology (11 papers) and CAR-T cell therapy research (9 papers). Craig B. Davis collaborates with scholars based in United States, France and Italy. Craig B. Davis's co-authors include Dan R. Littman, Derya Unutmaz, Connor Hill, Wilfried Ellmeier, Hongkui Deng, Nathaniel R. Landau, Rong Liu, Sunny Choe, P Di Marzio and Thomas J. Schall and has published in prestigious journals such as Nature, Cell and Nature Medicine.

In The Last Decade

Craig B. Davis

38 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of a major co-receptor for primary isolates of HIV-1

1996 3.0k citations Derya Unutmaz, Craig B. Davis et al. profile →

Peers

Countries citing papers authored by Craig B. Davis

Since Specialization

Citations

This map shows the geographic impact of Craig B. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig B. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig B. Davis more than expected).

Fields of papers citing papers by Craig B. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig B. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig B. Davis. The network helps show where Craig B. Davis may publish in the future.

Co-authorship network of co-authors of Craig B. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Craig B. Davis. A scholar is included among the top collaborators of Craig B. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig B. Davis. Craig B. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial 2023 ·Clinical & Translational Oncology ·Miguel Ángel Climent, Carlos Álvarez-Fernández, Rafael Morales, Pablo Maroto, Alejo Rodríguez‐Vida, María José Méndez-Vidal, Xavier García del Muro, Javier Puente, Núria Laínez, Sergio Vázquez‐Estévez, Daniel Castellano, (unknown), Jing Wang, Alessandra di Pietro, Craig B. Davis, (unknown), (unknown), Begoña P. Valderrama	3
2	Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer 2022 ·Frontiers in Immunology ·David S. Hong, Ajay K. Gopal, Alexander N. Shoushtari, Sandip Pravin Patel, Aiwu Ruth He, Toshihiko Doi, Suresh S. Ramalingam, Amita Patnaik, Shahneen Sandhu, Ying Chen, Craig B. Davis, Timothy S. Fisher, Bo Huang, Kolette D. Fly, Antoni Ribas	17
3	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial 2021 ·Nature Medicine ·Thomas Powles, Srikala S. Sridhar, Yohann Loriot, Joaquim Bellmunt, Xinmeng Jasmine Mu, Keith A. Ching, Jie Pu, Cora N. Sternberg, Daniel P. Petrylak, Rosa Tambaro, Louis Marie Dourthe, Carlos Álvarez-Fernández, Maureen J.B. Aarts, Alessandra di Pietro, Petros Grivas, Craig B. Davis	74
4	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas 2020 ·Clinical Cancer Research ·Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip Pravin Patel, Leslie Popplewell, Caron A. Jacobson, Xinmeng Jasmine Mu, Shibing Deng, Keith A. Ching, Ying Chen, Craig B. Davis, Bo Huang, Kolette D. Fly, Aron D. Thall, Adrian Woolfson, Nancy L. Bartlett	45
5	699O Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers 2020 ·Annals of Oncology ·Thomas Powles, Yohann Loriot, Joaquim Bellmunt, Cora N. Sternberg, Srikala S. Sridhar, Daniel P. Petrylak, Rosa Tambaro, Louis-Marie Dourthe, Carlos Álvarez-Fernández, (unknown), Xinmeng Jasmine Mu, Keith A. Ching, Jie Pu, Satrajit Roychoudhury, Craig B. Davis, Alessandra di Pietro, Petros Grivas	14
6	Standard machine learning approaches outperform deep representation learning on phenotype prediction from transcriptomics data 2020 ·BMC Bioinformatics ·(unknown), Jonathan R. Walsh, John M. Long, Craig B. Davis, Peter Henstock, Martin R. Hodge, Mateusz Maciejewski, Xinmeng Jasmine Mu, (unknown), Shanrong Zhao, Daniel Ziemek, Charles K. Fisher	47
7	Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood 2019 ·PLoS ONE ·Julie Rytlewski, Shibing Deng, Tao Xie, Craig B. Davis, Harlan Robins, Erik Yusko, Jadwiga Biénkowska	23
8	A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors 2019 ·Journal for ImmunoTherapy of Cancer ·Ezra E.W. Cohen, Michael J. Pishvaian, Dale R. Shepard, Ding Wang, Jared Weiss, Melissa L. Johnson, Christine H. Chung, Ying Chen, Bo Huang, Craig B. Davis, Francesca Toffalorio, Aron D. Thall, Steven Powell	45
9	Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer 2018 ·Clinical Cancer Research ·Neil H. Segal, Aiwu Ruth He, Toshihiko Doi, Ronald Levy, Shailender Bhatia, Michael J. Pishvaian, Rossano Cesari, Ying Chen, Craig B. Davis, Bo Huang, Aron D. Thall, Ajay K. Gopal	181
10	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer 2016 ·Gynecologic Oncology ·Josep M. del Campo, Michael J. Birrer, Craig B. Davis, Keiichi Fujiwara, Ashwin Gollerkeri, Martin Gore, Brett E. Houk, Susie Lau, Andrés Poveda, Antonio González-Martı́n, Carolyn Y. Muller, Kei Muro, Kristen J. Pierce, Mie Suzuki, Jennifer Vermette, Amit M. Oza	82
11	A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors 2014 ·Cancer Chemotherapy and Pharmacology ·Joaquı́n Mateo, Jordan Berlin, Johann S. de Bono, Roger B. Cohen, Vicki L. Keedy, Ganesh Mugundu, Lianglin Zhang, Antonello Abbattista, Craig B. Davis, Corrado Gallo Stampino, Hossein Borghaei	30
12	Y chromosome heterochromatin of differing lengths in two cell populations of the same individual 2005 ·Prenatal Diagnosis ·Yassmine Akkari, Helen J. Lawce, (unknown), (unknown), Craig B. Davis, (unknown), R. Ellen Magenis, Susan B. Olson	5
13	The Amino Terminus of Human CCR5 Is Required for Its Function as a Receptor for Diverse Human and Simian Immunodeficiency Virus Envelope Glycoproteins 1998 ·Virology ·(unknown), Douglas S. Kwon, Morris S. Jones, Craig B. Davis, Shana Marmon, Bruce L. Daugherty, Julie A. DeMartino, Martin S. Springer, Derya Unutmaz, Dan R. Littman	59
14	Disrupted development of thymocytes expressing a transgenic TCR upon CD4 overexpression 1995 ·International Immunology ·Craig B. Davis, (unknown)	12
15	Thymocyte lineage commitment: is it instructed to stochastic? 1994 ·Current Opinion in Immunology ·Craig B. Davis, Dan R. Littman	38
16	Signal Transduction During T Cell Development 1994 ·Advances in experimental medicine and biology ·Dan R. Littman, Craig B. Davis, Nigel Killeen, Hua Xu	4
17	CD4 function in thymocyte differentiation and T cell activation 1993 ·Philosophical Transactions of the Royal Society B Biological Sciences ·Nigel Killeen, Craig B. Davis, Kenneth C. Chu, Matthew Crooks, S Sawada, John D. Scarborough, (unknown), Susan G. Stuart, Hua Xu, Dan R. Littman	24
18	Evidence for a stochastic mechanism in the differentiation of mature subsets of T lymphocytes 1993 ·Cell ·Craig B. Davis, Nigel Killeen, Matthew Crooks, David H. Raulet, Dan R. Littman	198
19	Differential Involvement of Protein Tyrosine Kinases p56lck and p59fyn in T Cell Development 1992 ·Advances in experimental medicine and biology ·Nicolai S. C. van Oers, Alex M. Garvin, M. Cooke, Craig B. Davis, Dan R. Littman, Roger M. Perlmutter, H S Teh	5
20	Arsonate-specific murine T cell clones. V. Antigen presentation by L cells transfected with normal and mutant class II genes. 1989 ·The Journal of Immunology ·(unknown), Craig B. Davis, Penny Jones, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact